Podcast: Itchy Dog Diagnostics & Treatments with Dr. Lewis

Thomas P. Lewis II, DVM, DACVD, Dermatology for Animals, Gilbert, AZ

AudioDecember 2024ListenSponsored

Sponsored by Elanco

Is it time to scratch beneath the surface when it comes to the pruritic patient? In this episode of Clinician’s Brief Partner Podcast, host Dr. Beth sits down with dermatologist Dr. Tom Lewis to discuss his approach to the itchy dog, including when to focus on symptomatic therapy versus when to invest in a diagnostic investigation. Dr. Lewis shares how to define the goals of treatment and reviews the latest therapeutic options for addressing allergic disease in dogs.


INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-2291


Contact us:

  • Podcast@briefmedia.com

Where to find us:

The Team:

  • Beth Molleson, DVM - Host

  • Sarah Pate - Producer & Project Manager, Brief Studio

  • Randall Stupka - Podcast Production & Sound Editing

Sponsored Bysponsor logo